<DOC>
	<DOC>NCT00228059</DOC>
	<brief_summary>This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/day over 52 weeks in patients who completed the 3-week double-blind study CLIC477D2301.</brief_summary>
	<brief_title>An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.</brief_title>
	<detailed_description>A 52-week, open-label extension study to evaluate the safety and tolerability of licarbazepine 750- 2000 mg/day in the treatment of manic episodes of bipolar I disorder</detailed_description>
	<mesh_term>Disease</mesh_term>
	<criteria>1. written informed consent provided prior to participation in the extension study 2. successful completion of study CLIC477D2301 3. willingness and ability to comply with all study requirements 1. premature discontinuation from study CLIC477D2301 2. failure to comply with the study CLIC477D2301 protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Bipolar disorder, manic episode/treatment/licarbazepine</keyword>
</DOC>